Mazzoni Elisa, Pietrobon Silvia, Bilancia Miriam, Vinante Fabrizio, Rigo Antonella, Ferrarini Isacco, D'Agostino Antonio, Casali Maria Vittoria, Martini Fernanda, Tognon Mauro
Section of Pathology, Oncology and Experimental Biology, Department of Morphology, Surgery and Experimental Medicine, School of Medicine, University of Ferrara, Ferrara, Italy.
Section of Haematology, Department of Medicine, School of Medicine, University of Verona, Verona, Italy.
Cancer Immunol Immunother. 2017 Sep;66(9):1189-1198. doi: 10.1007/s00262-017-2008-9. Epub 2017 Apr 28.
A new immunological investigation was carried out to study the association between non-Hodgkin lymphoma and Simian virus 40 (SV40). To this end, a new indirect ELISA was employed with two mimotopes from SV40 large T antigen (Tag), the viral oncoprotein, to analyse for specific reactions to antibodies in sera from non-Hodgkin lymphoma patients and controls, represented by healthy subjects (HS) and breast carcinoma (BC) patients. This study allowed us to assay a new sera collection from non-Hodgkin lymphoma patients (NHL, n = 254). To verify the association between NHL and SV40 Tag, two totally independent cohorts were analysed: NHL1 n = 150 and NHL2 n = 104. The epidemiological survey included sera from HS1, n = 150; HS2, n = 104 and BC, n = 78. This new indirect ELISA revealed that antibodies against SV40 Tag mimotopes are detectable in NHL1 and NHL2 sera with a prevalence of 37 and 36%, respectively. The prevalence of SV40-antibodies detected in both NHL1 and NHL2 cohorts differs statistically from controls, at 19% for HS1 (p < 0.01), HS2 (p < 0.05) and BC patients (p < 0.05). This study, carried out with an immunological assay with specific Tag oncoprotein mimotopes of Simian virus 40, reports the presence of IgG antibodies against the large Tumour antigen in non-Hodgkin lymphomas for the first time. Our immunological data with two independent NHL cohorts show a statistically significant association between Simian virus 40 Tag and non-Hodgkin lymphoma. These results suggest that SV40-positive non-Hodgkin lymphomas could be treated differently from those tested SV40-negative.
开展了一项新的免疫学调查，以研究非霍奇金淋巴瘤与猿猴病毒40（SV40）之间的关联。为此，采用了一种新的间接酶联免疫吸附测定法（ELISA），使用来自SV40大T抗原（Tag）（病毒癌蛋白）的两个模拟表位，分析非霍奇金淋巴瘤患者血清以及以健康受试者（HS）和乳腺癌（BC）患者为代表的对照血清中抗体的特异性反应。本研究使我们能够检测来自非霍奇金淋巴瘤患者（NHL，n = 254）的一组新血清。为了验证NHL与SV40 Tag之间的关联，分析了两个完全独立的队列：NHL1，n = 150；NHL2，n = 104。流行病学调查纳入了来自HS1（n = 150）、HS2（n = 104）和BC（n = 78）的血清。这种新的间接ELISA显示，在NHL1和NHL2血清中可检测到针对SV40 Tag模拟表位的抗体，患病率分别为37%和36%。在NHL1和NHL2队列中检测到的SV40抗体患病率与对照组在统计学上存在差异，HS1为19%（p < 0.01），HS2（p < 0.05）和BC患者（p < 0.05）。这项使用猿猴病毒40特异性Tag癌蛋白模拟表位的免疫测定法进行的研究，首次报告了非霍奇金淋巴瘤中存在针对大肿瘤抗原的IgG抗体。我们对两个独立NHL队列的免疫学数据显示，猿猴病毒40 Tag与非霍奇金淋巴瘤之间存在统计学上的显著关联。这些结果表明，SV40阳性的非霍奇金淋巴瘤的治疗方式可能与SV40阴性的不同。
